<DOC>
	<DOCNO>NCT00955045</DOCNO>
	<brief_summary>The primary objective study establish long-term tolerability safety istradefylline treatment subject Parkinson 's disease treat levodopa/carbidopa . In addition , treatment response maintenance response assess .</brief_summary>
	<brief_title>A Long-Term , Safety Study With Flexible Dose Range KW-6002 Patients With Motor Response Complications Levodopa/Carbidopa Therapy</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<criteria>Eligible subject : male female least 30 year age complete participation prior doubleblind istradefylline trial meet United Kingdom 's Parkinson 's Disease Society ( UKPDS ) brain bank criterion ( Step 1 Step 2 ) Parkinson 's disease severity Parkinson 's disease define Stages 24 Modified Hoehn Yahr Scale OFF state treat levodopa least 1 year stable Parkinson 's disease regimen within normal therapeutic range include levodopa least 4 week Baseline currently take least 4 dos levodopa per day ( 3 dos per day least 2 dos contain slowrelease formulation ) predictable endofdose wearingoff</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>long-term tolerability safety</keyword>
	<keyword>istradefylline treatment</keyword>
	<keyword>levodopa/carbidopa</keyword>
</DOC>